Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Receives FDA Clearance for Phase-2 Clinical Trial of Lead Product ACP-01 in the United States

Marketwired August 10, 2015

Hemostemix Enrolls 20th Participant and Treats 15th in International Clinical Trial for Critical Limb Ischemia

Marketwired July 27, 2015

Hemostemix Enrolls 20th Participant and Treats 15th in International Clinical Trial for Critical Limb Ischemia

Marketwired July 27, 2015

Hemostemix Forms Strategic Alliance in Asia

Marketwired July 23, 2015

Hemostemix Posts Corporate Presentation on Company Website

Marketwired July 7, 2015

Hemostemix Enrolls Fifth Participant at Vancouver General Hospital in International Phase-2 Clinical Trial for Critical Limb Ischemia

Marketwired June 25, 2015

Hemostemix Prepares Investigational New Drug Application for Review by U.S. Food and Drug Administration for Company's ACP-01 Formulation to Treat Critical Limb Ischemia

Marketwired June 18, 2015

Hemostemix and Ludwig Boltzmann Institute for Experimental and Clinical Traumatology Enter Into Research Collaboration Agreement to Develop Hemostemix Regenerative Technology

Marketwired June 17, 2015

Hemostemix Names Dr. Rahul Sarugaser as Vice President of Business and Corporate Development

Marketwired June 16, 2015

Hemostemix to Present in Italy at the 2015 Gordon Research Conference on Assisted Circulation

Marketwired June 15, 2015

Hemostemix Receives Notice of Allowance for Additional U.S. Patent on ACP-01 Covering Autologous Cell Therapy for Critical Limb Ischemia (CLI)

Marketwired May 19, 2015

Hemostemix Retains Stonegate Capital Partners for Investor Relations

Marketwired May 11, 2015

Hemostemix to Present at the 2015 Annual Meeting of the Clinical Trials Association in Israel

Marketwired April 20, 2015

Hemostemix Expands Clinical Trial for Critical Limb Ischemia (CLI) to Four Sites in South Africa, Treats First South African Participant

Marketwired March 19, 2015

Hemostemix Expands Clinical Trial for Treating Critical Limb Ischemia to the Peter Munk Cardiac Centre at Toronto General Hospital

Marketwired March 6, 2015

Hemostemix Names Dr. Hardean E. Achneck as Vice President of Clinical Research and Operations

Marketwired February 2, 2015

Hemostemix Names Gerald D. Brennan, Jr. to Board of Directors; Announces Management Title Change

Marketwired January 28, 2015

Hemostemix Inc.: Corporate Update

Marketwired January 12, 2015

Hemostemix and Technical Ventures Complete RTO Transaction

Marketwired November 26, 2014

Technical Ventures RX Corp. Closes Financings and Plan of Arrangement

Marketwired November 12, 2014